e-learning
resources
Milan 2017
Sunday, 10.09.2017
Paediatric asthma: therapies and comorbidities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The impact of targeted therapy in children with uncontrolled allergic persistent severe asthma and nasal polyps
E. Vishneva (Moscow, Russian Federation)
Source:
International Congress 2017 – Paediatric asthma: therapies and comorbidities
Session:
Paediatric asthma: therapies and comorbidities
Session type:
Thematic Poster
Number:
1319
Disease area:
Airway diseases, Paediatric lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Vishneva (Moscow, Russian Federation). The impact of targeted therapy in children with uncontrolled allergic persistent severe asthma and nasal polyps. 1319
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype
Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections
Year: 2021
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Impact of biologic therapy in severe asthma with nasal polyps
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021
Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Dupilumab reduces blood and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps with and without comorbid asthma: SINUS-52 trial
Source: Virtual Congress 2020 – Phenotypes of asthma and COPD
Year: 2020
To assess the effects of combined nasal and inhaled corticosteroid in patients with asthma and persistent allergic rhinitis
Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases
Year: 2009
Tezepelumab efficacy in patients with severe, uncontrolled asthma and comorbid nasal polyps in NAVIGATOR
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009
Omalizumab in children with severe persistent allergic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Impact of mepolizumab in severe asthma with nasal polyps
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV
1
in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
IL-33 in patients with severe uncontrolled allergic asthma
Source: International Congress 2017 – "Alarming" immunological patterns in asthma
Year: 2017
Persistent airway inflammation in young allergic wheezing children treated with inhaled corticosteroids
Source: Annual Congress 2003 - Current issues on wheezing in infancy
Year: 2003
Immunological effectiveness of N-acetylcystein in complex therapy in severe persistent bronchial asthma patients
Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma
Year: 2008
Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy
Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD
Year: 2018
Comparison of residual eosinophilic inflammation in the distal airway of patients with well-controlled asthma using different drug combinations of asthma treatment
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008
Immunotherapy in severe asthma
Source: ERS webinar 2021: Immunotherapy in severe asthma
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept